Table 4 Sample size to detect prevalence of primary outcomes among ZIKV infected symptomatic and asymptomatic participants
Proportion of women with ZIKV symptoms | Prevalence of congenital malformations and adverse fetal outcomes among uninfected and asymptomatic women | Prevalence of congenital malformations and adverse fetal outcomes among ZIKV symptomatic women | Total number of women | Power |
|---|---|---|---|---|
3% | 1% | 3% | 6000 | 57% |
8000 | 69% | |||
10,000 | 77% | |||
4% | 6000 | 68% | ||
8000 | 78% | |||
10,000 | 85% | |||
5% | 6000 | 75% | ||
8000 | 84% | |||
10,000 | 91% | |||
4% | 6000 | 94% | ||
8000 | 97% | |||
10,000 | 99% |